Research programme: HDAC6 inhibitors - Eikonizo Therapeutics
Alternative Names: HDAC6i in non-CNS indicationsLatest Information Update: 28 Jul 2024
At a glance
- Originator Eikonizo Therapeutics
- Class Small molecules
- Mechanism of Action HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Unspecified
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Unspecified in USA
- 22 Jun 2020 Preclinical trials in Unspecified in USA (unspecified route) (Eikonizo Therapeutics pipeline, June 2020)